Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 12/20 | 0.57 |
| ▸ | ESR1 | P03372 | 9/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | AMY1A | P0DUB6 | 3/20 | 0.41 |
| ▸ | CTSG | P08311 | 1/20 | 0.41 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | CTRC | Q99895 | 1/20 | 0.41 |
| ▸ | KLK14 | Q9P0G3 | 1/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4487172 | 0.82 | ESR2 (0.46) | ESR2ESR1CTSGKLK7CTRC | |
| SCHEMBL4464248 | 0.79 | HDAC6 (0.56) | ESR2ESR1HDAC6 | |
| SCHEMBL4463663 | 0.77 | ESR1 (0.54) | ESR2ESR1GPR119HDAC6 | |
| SCHEMBL17554127 | 0.76 | CTSG (0.62) | GPR119AMY1ACTSGKLK7CTRC | |
| SCHEMBL5417126 | 0.75 | ESR1 (0.51) | ESR2ESR1HDAC6 | |
| SCHEMBL1377426 | 0.73 | ESR2 (1.00) | ESR2ESR1HDAC6 | |
| SCHEMBL6518045 | 0.73 | ESR1 (0.52) | ESR2ESR1HDAC6 | |
| SCHEMBL4473598 | 0.72 | ESR1 (0.45) | ESR2ESR1CTSGKLK7CTRC | |
| SCHEMBL17554168 | 0.72 | C1R (0.65) | CTSGKLK7CTRCKLK14KLK5 | |
| SCHEMBL17554059 | 0.71 | ELANE (0.54) | GPR119CTSGKLK7CTRCKLK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531564-B2 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1982713-A2 | Substituted benzoxazoles and analogues as estrogenic agents | Wyeth (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20080255057-A1 | PRODRUG SUBSTITUTED BENZOXAZOLES AS ESTROGENIC AGENTS | WYETH (US) | 2008-10-16 | — | — | US | disclosed |
| US-20070167503-A1 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2007-07-19 | — | — | US | disclosed |
| US-7148247-B2 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2006-12-12 | — | — | US | disclosed |
| US-7129258-B2 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2006-10-31 | — | — | US | disclosed |
| US-20060046968-A1 | Prodrug substituted benzoxazoles as estrogenic agents | WYETH (US) | 2006-03-02 | — | — | US | disclosed |
| US-20050239851-A1 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2005-10-27 | — | — | US | disclosed |
| US-20050080117-A1 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2005-04-14 | — | — | US | disclosed |
| US-6794403-B2 | FOR TREATING OR INHIBITING INFLAMMATORY BOWEL DISEASE, CROHN'S DISEASE, ULCERATIVE PROCTITIS OR COLITIS PROSTATIC HYPERTROPHY, UTERINE LEIOMYOMAS, BREAST CANCER, ENDOMETRIAL CANCER, CARDIOVASCULAR DISEASE, ALZHEIMER'S DISEASE | WYETH | 2004-09-21 | — | — | US | disclosed |
| EP-1451165-A1 | SUBSTITUTED BENZOXAZOLES AND ANALOGUES AS ESTROGENIC AGENTS | Wyeth (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20030199562-A1 | Substituted benzoxazoles as estrogenic agents | WYETH | 2003-10-23 | — | — | US | disclosed |
| WO-2003050095-A1 | SUBSTITUTED BENZOXAZOLES AND ANALOGUES AS ESTROGENIC AGENTS | WYETH (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255057-A1 | PRODRUG SUBSTITUTED BENZOXAZOLES AS ESTROGENIC AGENTS | ESR1, CYP19A1, ESR2 | ESR2 3/4885ESR1 1/4885GPR119 83/4885 |
| US-20050239851-A1 | Substituted benzoxazoles as estrogenic agents | ESR1, ESR2, ESRRA | ESR2 2/4885ESR1 1/4885GPR119 60/4885 |
| US-20050080117-A1 | Substituted benzoxazoles as estrogenic agents | ESR1, ESR2, ESRRA | ESR2 2/4885ESR1 1/4885GPR119 60/4885 |
| US-20030199562-A1 | Substituted benzoxazoles as estrogenic agents | ESR1, ESR2, ESRRA | ESR2 2/4885ESR1 1/4885GPR119 95/4885 |
| US-20070167503-A1 | Substituted benzoxazoles as estrogenic agents | ESR1, ESR2, ESRRA | ESR2 2/4885ESR1 1/4885GPR119 60/4885 |
| US-20060046968-A1 | Prodrug substituted benzoxazoles as estrogenic agents | ESR1, CYP19A1, ESR2 | ESR2 3/4885ESR1 1/4885GPR119 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.